Brand-name diabetes drugs more likely with Part D

06/10/2013 | Reuters · MedPage Today (free registration)

A study in the Annals of Internal Medicine found Medicare Part D beneficiaries were up to three times as likely to be prescribed brand-name diabetes treatments instead of generics compared with patients covered by the Department of Veterans Affairs. Researchers estimated that greater use of generics could have lowered Medicare costs by $1.4 billion in 2008. "It represents essentially spending that is probably not necessary for most people," said lead researcher Dr. Walid Gellad of the Veterans Affairs Pittsburgh Healthcare System.

View Full Article in:

Reuters · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA